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Abstract 
Carotenoids are very abundant in nature and their consumption has numerous positive 
health outcomes. There are two known enzymes that are responsible for cleaving carotenoids in 
to their metabolites. β-carotene is cleaved by carotenoid-15,15'-oxygenase (CMO-I), to 
eventually form biologically-active retinoids. Lycopene is a non-provitamin A carotenoid and the 
most abundant carotenoid in tomatoes. Lycopene is a poor substrate for CMO-I, but our lab 
along with other has proposed that the enzyme carotenoid 9'10'-monoxygenase (CMO-II) can 
oxidatively cleave lycopene. In order to assess the impact of dietary carotenoids and their 
metabolites on lipid metabolism in female mice, CMO-I KO, CMO-II KO or wild type (WT) 
mice, 29-31 weeks old, were fed the following AIN-93G based diets for either 4 or 30 days: 
lycopene beadlet, 10% tomato powder, and their respective controls. We hypothesized that mice 
lacking either carotenoid cleavage enzyme would have altered serum and hepatic lipids 
compared to WT mice while lycopene or tomato powder might modulate these effects. Our data 
demonstrate that a lack of CMO-I or CMO-II altered reproductive organ weights and lipid status, 
and feeding carotenoid-containing diets had modest impact on lipid metabolism in these mice. 
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Chapter I 
Literature Review 
Introduction 
 Carotenoids occur throughout nature, and more than 600 carotenoids have been 
discovered. Most carotenoids are derived from the same C40, tetraterpene structure and are 
commonly produced in the photosynthetic tissues of plants and algae. They can be grouped 
either as hydrocarbons called carotenes, or their oxygenated derivatives called xanthophylls (1). 
Carotenoids are not known to be produced by mammals, yet their consumption from the diet is 
important for vitamin A production, because some carotenoids have provitamin A activity (β-
carotene, α-carotene, and β-cryptoxanthin). Provitamin A carotenoid consumption helps to 
alleviate vitamin A deficiency symptoms which can lead to blindness, increase mortality, 
impaired immune function, and numerous other negative health outcomes. Carotenoids may also 
have anticancer activity and have been shown to influence the risk and progression of cancers of 
the lung, breast, prostate, cervix and ovary (2). There is high variability in the provitamin A 
activity of β-carotene (3), which could possibly be due to differences in intestinal conversion of 
β-carotene to vitamin A, inefficient incorporation of β-carotene into chylomicrons or higher rates 
of β-carotene clearance as a result of abnormal lipoprotein metabolism. 
Carotenoid Cleavage Enzymes 
Carotene-15,15’-monooxygenase  
In order for provitamin A carotenoids to be converted into vitamin A they must first be 
cleaved by carotene-15,15’-monooxygenase (CMO-I), an enzyme initially identified from the 
supernatant solution of rat liver and intestine (4). Cleavage occurs at the central carbon double 
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bond, and theoretically creates 2 molecules of retinal, which can be reduced to retinol (5). 
Additionally researchers have found that oxygen is necessary in order for this cleavage to take 
place, and that CMO-I is a nonheme iron-containing enzyme (4, 5). Cleavage of β-carotene is an 
important source of retinoic acid in various tissues suggesting that this cleavage plays a vital role 
in retinoid homeostasis (6). CMO-I has been identified as a cytoplasmic enzyme (7). CMO-I is 
expressed in the human intestinal tract with the highest mRNA expression being in the jejunum. 
CMO-I is also expressed in many other tissues including the liver, kidney, prostate, testis, ovary, 
colon and skeletal muscle (7).   
Carotene-9’10’-monooxygenase 
Another carotenoid cleavage enzyme, carotene-9’10’-monooxygenase (CMO-II), is 
responsible for the asymmetric cleavage of β-carotene to form β-apo-10’carotenal and β-ionone 
(8). CMO-II cleaves at a different pH than CMO-I (8.5 vs. 7.7) which suggests that these 
enzymes perform different carotenoid cleavage functions (9). CMO-II was identified as a 
mitochondrial protein and is thought to protect against oxidative damage caused by excess 
carotenoid accumulation (10). mRNA expression of CMO-II was found in the same tissues as 
CMO-I (small intestine, liver, kidney, and testes), and also in spleen, brain, lung and heart (7, 8) 
Single nucleotide polymorphisms 
Two nonsynonymous single nucleotide polymorphisms (SNPs) were identified (R267S 
and A379V) in the human CMO-I coding region, and the variant allele frequencies in a female 
Northern European cohort of these SNPs were 42 and 24% respectively (11). Leung et al. 
analyzed plasma samples from 28 female volunteers and found that those with the A379V 
variant allele, and the combined R267S and A379V variant alleles had significantly higher 
concentrations of fasting plasma β-carotene. These findings are important because in double 
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tracer studies, 27-45% of subjects were identified as poor converters of β-carotene and these and 
other SNPs are most likely the reasons for this poor converter phenotype (12-14). 
 Recently, SNPs within the human CMO-II gene have been described (15). Female variant 
allele carriers of common CMO-II SNPs have been found to have reduced fasting HDL-
cholesterol concentrations compared to wild-type carriers (abstract data) (16).  
Lycopene 
Absorption and Transport 
Lycopene, a non-provitamin A carotenoid, is the most abundant carotenoid in tomatoes 
and is responsible for their red pigment (17). In order for lycopene, along with other dietary 
carotenoids, to be absorbed optimally a few key events must occur; 1) the food matrix must be 
digested for release of the carotenoids, 2) lipid micelles must be formed, 3) carotenoids must be 
taken up into the intestinal mucosal cells, and 4) carotenoids and their metabolic products must 
be transported to the lymphatic circulation (18). In order to digest the food matrix of lycopene-
containing foods, mild heating has been found to increase the plasma appearance of lycopene 
from tomato juice compared to tomato juice that has not been heated prior to ingestion (19). In 
addition, incorporation of fat into a carotenoid-containing meal can aid in absorption by 
stimulating bile production, and increasing micelle formation. It has also been suggested that cis-
isomers of lycopene are preferentially absorbed when compared to all-trans lycopene isomers 
(19). Another study that supports this suggestion, found that cis-isomers preferentially 
accumulated in prostate tissues of men (20). Once lycopene is absorbed into the mucosal cells it 
is then transported in the lymph system to the liver for repackaging into lipoproteins like very 
low density lipoproteins (VLDL) and low density lipoproteins (LDL). Fasting blood analysis 
revealed that lycopene is mainly carried in the LDL fraction (21).  
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Cleavage 
In order for cleavage of lycopene by CMO-I to occur, there must be very high concentrations 
of lycopene present (6). Incubation of lycopene and a Drosophila homologue of CMO-I in rat 
liver and intestine, showed no lycopene cleavage products (22). In addition to a lack of activity 
of human CMO-I on lycopene, researchers have also seen no activity of human CMO-I on 
zeaxanthan (7). As a result of this data, researchers concluded that another enzyme must then be 
responsible for cleavage of lycopene. Consequently, CMO-II has been shown to cleave lycopene 
in E.coli strains transfected with either mouse or ferret CMO-II (8, 9). Animal studies from our 
laboratory support this theory that CMO-II cleaves lycopene, as CMO-II KO
 
mice fed lycopene 
or tomato powder had greater tissue lycopene accumulation compared to wild-type mice (23, 
24). In addition, in vitro evidence suggests that CMO-II cleaves xanthophylls at the 9’,10’ 
carbon double bond (10).  
Action 
Lycopene has been classified as an antioxidant and has been shown to scavenge the 
ABTS˙+ radical cation more extensively than β-carotene in an in vitro antioxidant activity study 
(25). Lycopene’s action as an antioxidant has been associated with a lower incidence of 
metabolic syndrome (26). Metabolic syndrome was initially described as a group of diseases 
including glucose intolerance, dyslipidemia, high blood pressure, and coronary heart disease (27) 
and now includes excess weight, low concentrations of HDL and hypertriglyceridemia (28). 
Sluijs et al. found that with higher intake levels of lycopene, there was a decreased trend in 
prevalence of metabolic syndrome (26). However, in another study that analyzed the Third 
National Health and Nutrition Examination Survey (NHANES III) data on the association of 
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metabolic syndrome and antioxidant concentrations, lycopene concentrations were not associated 
with a decrease in metabolic syndrome (28).    
As mentioned before, carotenoids have been shown to have anticancer abilities (2). In 
epidemiological studies high levels of serum lycopene were associated with a reduced risk of 
prostate cancer (29, 30). Our lab has demonstrated a possible mechanism in which lycopene, and 
its metabolites, decrease prostate cancer progression. Androgen-independent prostate cancer 
cells (DU145 cells) were treated with a supraphysiolocgical doses of either lycopene or apo-12'-
lycopenal. A reduction in the proliferation of these cells was seen 72 hours post treatment of 
either lycopene or apo-12'-lycopenal. The mechanism, to some extent, was identified as 
inhibition of normal cell cycle progression (31). Many other studies have investigated additional 
mechanisms of lycopene’s action in reducing prostate cancer. These mechanisms include the 
ability to increase the cell-cell communication pathway by an increasing the gap junction 
communication protein, connexin 43 (32, 33). Our lab, however, failed to find that lycopene 
affected connexin 43 (31).   
PPARs and their target genes 
Peroxisomal proliferator-activated receptor (PPAR) gamma and alpha are part of the 
same nuclear hormone receptor superfamily and are ligand dependent transcription factors. 
PPARγ is necessary for fat cell formation (34) and, as a result, PPARγ is the target of glitazones, 
especially thiazolidinediones (TZDs), which are used as antidiabetic agents (35). PPARα is 
responsible for modulating oxidation of fatty acids in the liver (36). Fibrates, which are PPARα 
activators, are used to protect against coronary artery disease by increasing gene expression of 
apoliopoproteins in HDL, resulting in an increase in reverse cholesterol transport (reviewed in 
(36)).  
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A nuclear factor, adipocyte regulatory factor 6 (ARF6), was found to bind to a 
peroxisome proliferator response element (PPRE)-like sequence in the fatty acid binding protein 
4 (FABP4) promoter region, and was shown to enhance transcription of FABP4 (37-39). This 
factor was later discovered to be the PPARγ and RXRα heterodimeric complex (40). 
Additionally, heterodimerization of PPARγ and RXRα in the PPRE of the promoter region of 
CMO-I regulates the expression of this gene (41). These discoveries demonstrate the similarities 
between activation of FABP4 and CMO-I by PPARγ and RXRα.  
PPARα was also found to heterodimerize with RXRα in the PPRE of the promoter 
regions of genes involved in β-oxidation, most notably acyl-CoA oxidase (ACOX) (42). PPARα 
was observed to stimulate the promoter of ACOX by 3-fold when a PPARα expression vector 
was co-transfected into HeLa cells with a rat ACOX gene promoter region (43).  
Lycopene has been hypothesized to exhibit effects on PPARγ expression. In one study, 
LNCaP (an androgen-dependent prostate cancer cell line) cells were treated with lycopene. After 
24 hours of lycopene treatment, there was an increase in both protein and mRNA expression of 
PPARγ (44). In another in vitro study, lycopene was also shown to reduce the intracellular levels 
of cholesterol in human macrophages by increasing PPARγ mRNA expression, which enhanced 
the expression of ATP-binding cassette protein A1 (ABCA1) and caveolin-1 (cav-1), and as a 
result, decreased 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) 
(45). Our lab also looked at lycopene’s effects on PPARγ mRNA expression, but found that 
lycopene feeding decreased PPARγ mRNA expression in rat kidneys and adrenals (46).(42) 
CMO-I KO and CMO-II KO mice phenotype 
In addition to carotenoid metabolism, evidence suggests that the CMO-I enzyme is more 
broadly involved in lipid metabolism, and some of the actions of CMO-I may be independent of 
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carotenoid consumption. As detailed below, mice lacking the CMO-I enzyme have altered lipid 
metabolism. There are only a few papers published from studies on CMO-II KO mice and no 
details on altered lipid metabolism in this phenotype have been reported. CMO-I KO mice were 
developed by researchers at DSM Nutritional Products (Kaiseraugst, Switzerland)(47). CMO-II 
KO mice were developed by DSM and by the Institut für Immunbiologie at the University of 
Freiburg (Freiberg, Germany)(10).  
Body and organ weights 
In the literature there is evidence that the CMO-I genotype impacts body and tissue 
weights. Both male and female CMO-I KO mice were heavier upon completion of a cholesterol-
supplemented lycopene-containing diet study compared to WT mice (24). In another study, 
female CMO-I KO mice, compared to WT mice, at the start of a study had lower average body 
weights, but these mice showed a tendency to gain more weight during a 14 week feeding period 
than WT mice (48). As a result, at the end of this study the CMO-I KO mice weighed the same 
as the WT mice. In an 8 week high fat feeding study, female CMO-I KO mice gained 
significantly more weight than female WT mice (47).  
Reproductive organ weights have also been measured in CMO-I KO and CMO-II KO 
mice and have been found to be significantly different in weight as a percent of body weight. In 
one study from our lab, CMO-I KO female mice had significantly smaller uteri compared to WT 
mice independent of dietary carotenoids (24). In another study, which simultaneously compared 
the effects of two tomato carotenoid diets and two control diets, male CMO-II
 
KO mice had 
smaller testes and seminal vesicles as a percentage of body weight compared to WT mice 
independent of tomato carotenoid feeding (23).  
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Hepatic Lipids 
Hepatic lipids have also been measured in a few CMO-I KO studies and one study with 
CMO-II KO mice. Researchers were interested in determining if any phenotypic alterations, in 
addition to impaired β-carotene metabolism, were associated with a CMO-I deficiency (47). 
They found that when compared to WT mice, CMO-I KO mice accumulated more hepatic lipids 
when fed diets with β-carotene with a very low level of vitamin A (150 IU vitamin A/kg diet) 
(47). In order to determine if the development of fatty liver could be prevented in these CMO-I 
KO mice, Hessel and coworkers fed preformed vitamin A to 25-week old CMO-I KO mice and 
WT mice (14,000 IU vitamin A /kg diet). The CMO-I KO mice still had significantly elevated 
levels of lipids in the liver compared to WT mice and had significantly more triglycerides in their 
livers (47). These results were not reproduced in a study where cholesterol-containing diets were 
fed (1500 IU vitamin A/kg diet) (24).  
In order to determine the hepatic lipid content in CMO-II KO mice, heterozygous (+/-) 
and homozygous (-/-) CMO-II KO mice and WT mice were fed a vitamin A deficient diet 
supplemented with a xanthophyll, zeaxanthin (0.05mg zeaxanthin/g diet). Zeaxanthin feeding 
induced hepatic lipid droplet formation in the livers of male and female CMO-II
-/-
 and CMO-II
+/- 
mice, but not in zeaxanthin/chow-fed WT mice nor in chow-fed CMO-II
-/- 
mice (10). These 
results suggest that supplementation with certain carotenoids may contribute to lipid 
accumulation in the liver in this phenotype.  
Serum Cholesterol 
There may also be a relationship between CMO-I genotype, dietary carotenoids, and 
serum cholesterol levels. Lycopene feeding significantly lowered serum cholesterol levels in 
CMO-I KO mice fed a cholesterol-containing diet compared to CMO-I KO mice fed a lycopene-
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free, cholesterol diet (24). In another study both male and female CMO-I KO mice, under 
standard dietary conditions, did not show differences in serum cholesterol ester and triglyceride 
levels compared to WT mice (47). However, levels of unesterified serum free fatty acids (FFAs) 
were significantly elevated in these mice compared to WT mice. Interestingly, when Hessel and 
coworkers fed 20-week-old female CMO-I KO and WT mice a high fat (30% w/w) diet, serum 
cholesterol ester levels were significantly higher in CMO-I KO mice compared to WT mice. 
Serum FFAs were also increased in these mice. These researchers hypothesized that since the 
rate of hepatic uptake of FFA is directly proportional to serum concentrations of FFA, the 
increase in FFAs in the serum may explain why their CMO-I animals developed fatty liver (47).  
PPARs and their target genes 
 As stated before, PPARγ and RXRα heterodimerize in the PPRE of the promoter region 
of CMO-I and regulates its expression, and as a consequence there has been interest in the 
expression of PPARγ and its target genes in CMO-I KO mice. One study fed either a β-carotene 
supplemented diet (150 mg β-carotene/kg diet) or a control diet to female CMO-I KO and WT 
mice for 14 weeks, and found β-carotene supplementation down-regulated mRNA expression of 
PPARγ in WT mice, but not CMO-I KO mice. These researchers also determined that there was 
a decreased mRNA expression of lipoprotein lipase (LPL), a target of PPARγ (48). Hessel and 
colleges also measured PPARγ target genes in the adipose of their mice (47). They found mRNA 
expression of FABP4 to be significantly elevated in CMO-I KO mice compared to WT mice. 
 PPARα is also a PPAR of interest because of its involvement in fatty acid catabolism. 
When the mRNA expression of PPARα was measured in CMO-I KO and WT mice, researchers 
did not find any differences between genotypes (47). However, when the mRNA expression of 
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ACOX1, a PPARα target gene, was measured in these same mice they found CMO-I KO mice to 
have significantly elevated levels compared to WT mice (47).  
Aims of thesis 
In summary, while CMO-I and II enzymes are known to play a primary role in cleavage 
of carotenoids, some evidence from mice lacking one of these enzymes suggests that these genes 
have pleiotropic effects ranging from lipid metabolism to reproductive organ growth.  The goals 
of this thesis are to: (1) examine the role of CMO-I and II in whole body and reproductive organ 
growth and lipid metabolism in female mice and to (2) investigate differences in expression of 
PPARγ and PPARα and selected genes they regulate (3) determine if there is a modulating effect 
of tomato carotenoids, on serum and hepatic lipids. We hypothesized that CMO-I KO mice 
would have altered lipid metabolism compared to WT mice independent of dietary carotenoids 
based on the work by Hessel and coworkers (47). We also hypothesized that CMO-II KO mice 
would have altered lipid metabolism compared to WT mice and that tomato carotenoids would 
impact hepatic lipids based on the results from Amengual and colleges (10). Since there were no 
prior papers published on CMO-II KO mice when this project began, we based this hypothesis 
on what was observed in CMO-I KO mice. Our goal for this work was to focus on female mice 
because this laboratory has yet to investigate the impact of lycopene or tomato powder on 
females, especially regarding reproductive organs weights and lipid metabolism. 
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Chapter II 
Lycopene and Tomato Powder Marginally Impact Lipid Status in Female 
CMO-I KO and CMO-II KO mice 
Abstract 
The β-carotene central cleavage enzyme, carotenoid-15,15'-oxygenase (CMO-I) is 
responsible for cleaving the carotenoid β-carotene to form vitamin A and with further 
metabolism, the production of biologically-active retinoids. It was previously found that adult 
mice lacking this enzyme have altered lipid metabolism resulting in fatty liver development. 
Lycopene, a non-provitamin A carotenoid and the most abundant carotenoid in tomatoes, is a 
poor substrate for CMO-I. Instead, lycopene can be oxidatively cleaved by carotenoid 9'10'-
monoxygenase (CMO-II). Lycopene has been shown in our lab to decrease the expression of 
peroxisome proliferator-activated receptor gamma (PPARγ), which is essential for adipogenesis, 
in some rat tissues. Interestingly, there is a peroxisome proliferator response element (PPRE) in 
the promoter region of CMO-I. In order to assess the impact of dietary carotenoids and their 
metabolites on lipid metabolism, female CMO-I KO, CMO-II KO or wild type (WT) mice, 29-
31 weeks old, were fed the following AIN-93G based diets for 4 or 30 days: lycopene beadlet, 
10% tomato powder, and their respective controls. We hypothesized that mice lacking either 
carotenoid cleavage enzyme would have altered serum and hepatic lipids compared to WT mice 
while lycopene or tomato powder might modulate these effects. The results show greater hepatic 
lipid accumulation in both CMO-I KO mice and CMO-II KO mice compared to WT mice. There 
were some genotype and diet effects in serum and hepatic cholesterol in each mouse strain 
compared to WT mice. Furthermore, we found genotypic differences in mRNA expression of 
PPARα in the liver and PPARγ and FABP4 expression in the adipose tissue and the liver. 
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Reproductive organ weights, as a percent of body weight were smaller in CMO-I KO and CMO-
II KO mice compared to WT mice. Interestingly, we found the reproductive capacity of our 
breeding colonies of CMO-II KO mice to be decreased (average~2 pups/ litter) compared to 
CMO-I KO mice (average~5 pups/ litter) fed a standard chow diet. These data demonstrate that a 
lack of CMO-I or CMO-II altered reproductive organ weights and lipid status, and feeding 
carotenoid-containing diets had modest impact on lipid metabolism in these mice. 
Introduction 
 Hundreds of carotenoids have been discovered and are commonly produced in the 
photosynthetic tissues of plants. They can be grouped as either the hydrocarbon carotenes or 
xanthophylls (which are oxygenated carotenoids) (1). Provitamin A carotenoid (β-carotene, α-
carotene, and β-cryptoxanthin) consumption helps to alleviate vitamin A deficiency symptoms 
which can lead to numerous negative health outcomes. Carotenoids, even non-provitmin A 
carotenoids like lycopene, may also have anticancer activity and have been shown to influence 
the risk and progression of cancers, most notably prostate cancer (2, 29, 30).  
Mice lacking CMO-I and CMO-II, enzymes responsible for cleaving carotenoids 
centrally (4) and eccentrically, respectively (8), have been used as models to investigate 
biological effects of carotenoids and their metabolites. Carotenoid accumulation studies in mice 
lacking either CMO-I or CMO-II demonstrate differences in accumulation of lycopene 
depending on which carotenoid is ablated (23, 24). In addition to the results published on 
bioaccumulation of lycopene in these KO mice, investigators have noted the development of 
hepatic steatosis in both CMO-I KO mice (47) and CMO-II KO mice (10).  Our lab is interested 
in the role of tomato carotenoids, especially lycopene, and their effects on various health 
outcomes such as prostate cancer (23, 49-51). Based on the literature, CMO-I KO mice and 
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CMO-II KO mice apparently have altered lipid metabolism and we were interested to investigate 
if feeding lycopene or tomato powder would modulate different measures of lipid status such as 
hepatic lipid deposition and lipid metabolism-related genes in our female CMO-I KO and CMO-
II KO mice. 
Materials and Methods 
Animals  
All animal handling and surgical procedures were approved by the University of Illinois 
Institutional Animal Care and Use Committee. The generation of CMO-I KO mice and CMO-II 
KO mice has been previously published (10, 47). Female C57BL/6 x 129/SvJ (F1) mice (n~80) 
were purchased at 4-8 weeks of age for use as wild-type (WT) mice from Jackson Laboratory 
(Bar Harbor, ME) and were kept in the University of Illinois animal facility and fed rodent chow 
until they reached the appropriate age to go on study (29-32 week of age). CMO-I KO 
(B6;129S6-Bcmo1tm1Dnp) mice and CMO-II KO (B6;129S6-Bcdo2tm1Dnp) mice were bred at 
the animal facility. Confirmation of the genotype was previously described by using genomic 
DNA from mouse tail biopsies and the Extract-N-Amp Tissue PCR Kit (Sigma, St. Louis, MO) 
(23). CMO-I KO and CMO-II KO mice were bred with siblings to ensure homozygous knock-
outs. They were given food and water ab libitum before and during the studies. 25-30 week old 
female WT, CMO-I KO and CMO-II KO mice consumed an AIN-93G diet for one week prior to 
randomization onto experimental diets.  
Diets  
A powdered AIN-93G diet was used for the foundation of all diets. Fresh diet was 
provided every 48 hours and new diets were made monthly. The diets were stored in the dark at 
4ºC.  For the lycopene diet, 1g of 10% water soluble lycopene beadlets/kg diet was added (DSM, 
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Basel, Switzerland). The lycopene diet for the 30 day study contained 152 ± 7 nMol lycopene/g 
diet and for the 4 day study there was 176 ± 34 nMol lycopene/g diet (Table 1). For the tomato 
powder diet, 10% tomato powder (Futureceuticals, Momence, IL) was added to the AIN-93G 
diet. The 30 day study tomato powder diet contained 181 ± 42 nMol lycopene/g diet and there 
was 235 ± 19 nMol lycopene/g diet in the 4 day study. Additionally, vitamin A levels were 
reduced to low, but not deficient levels of 1500 IU vitamin A (retinol) provided by retinyl 
palmitate per kg diet (NRC 2,400 IU/kg diet) in all diets to help optimize absorption of 
carotenoids as discussed previously (24, 47). 
Study Design  
When WT mice were received from Jackson Labs they were separated by sex and placed 
two to a cage. All mice were given rodent chow until they were placed on the AIN-93G 
acclimation diet one week prior to randomization to the feeding studies. We fed animals for both 
30 and 4 days. We wanted to determine if feeding carotenoids for different lengths of time could 
show the same results. Additionally, we wanted to determine if any dietary results could be seen 
after just 4 days of feeding. For both the 30 day and 4 day studies, mice were randomly assigned 
to one of four experimental tomato carotenoid-containing diets; 10% tomato powder, or 10% 
water-soluble lycopene beadlet or their respective controls (Figure 1). For statistical purposes 
the tomato powder group was compared to its AIN-93G control group while the lycopene 
beadlet-fed group was compared to their placebo beadlet control group (n~10 per 
genotype/diet/study). Mice were weighed every two days while on the 30 day study and mice 
were weighed daily for the 4 day study. At the conclusion of the studies, mice were fasted 3 
hours prior to sacrifice. The mice were then asphyxiated by CO2 and cardiac puncture was used 
to remove blood. Blood was placed on ice and protected from the light. Serum was separated 
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from the collected blood via centrifugation (1500xG for 20min at 4ºC). Liver, spleen, kidneys, 
uteri, ovaries, gonadal and perirenal adipose tissue (visceral adipose) were removed, frozen in 
liquid nitrogen and then stored at -80ºC. A small portion of the liver was saved in 10 % formalin 
(Sigma-Aldrich, St. Louis, MO) and after 24 hours at room temperature, the samples were placed 
in the refrigerator in 70% ethanol before transfer to the Comparative Biosciences Histology 
Laboratory at University of Illinois-Urbana/Champaign for histological analysis.  
Hepatic Lipid Extraction  
Total liver lipids were extracted using a modification of the Folch method (1, 24). 
Briefly, the liver sample (~0.3
 
g) was homoginized in chloroform: methanol (1:1) (Fisher 
Scientific, Pittsburg, PA.), and
 
filtered by gravity using Whatman 110mm filter paper (Fisher 
Scientific). The mixture was washed with 0.29%
 
sodium chloride solution, and then centrifuged 
at 183 x g for 5 min at
 
25°C. Chloroform was added to the mixture to ensure removal of lipids 
from the top layer. The sample was centrifuged again at 183 x g for 5 min at
 
25°C and the top 
layer was discarded. These steps were repeated 2 more times to guarantee complete isolation of 
lipids from our samples. The remaining solution
 
was evaporated under a hood, placed to dry in a 
desiccator for at least 48
 
hours, and then weighed to determine total lipids.  
Serum and Hepatic Cholesterol Analysis  
Serum and hepatic total cholesterol were measured using an enzymatic colorimetric assay 
(Wako Chemicals USA, Richmond, VA). For hepatic cholesterol analysis, 1mL 10% Triton 100x 
(Sigma-Aldrich, St. Louis, MO) in isopropanol (Fisher Scientific) was added to our previously-
extracted liver lipid samples and vortexed. Serum and liver lipid samples were then analyzed 
using the kit’s instructions. Briefly, 20 µL of either serum or liver lipid extracts were mixed with 
2 mL buffer (50μM Good’s Buffer) mixed with the color reagent (cholesterol esterase, 
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cholesterol oxidase, peroxidase, DAOS, aminoantipyrine and ascorbate oxidase). The sample 
results were compared with a standard curve at concentrations of 100, 200, 397.4, 592.2 mg/dL. 
Plates were read at a wavelength of 600nm.  
mRNA Expression Analysis  
RNA isolation was done using a previously published method from manufacturer’s 
instructions. Briefly, total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA) in 
combination with homogenization. To determine the quality and concentration of the extracted 
mRNA, electrophoresis and spectrophotometry were used. If the mRNA was considered of good 
quality, cDNA was synthesized using a High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA). mRNA expression of these genes were measured via 
real-time PCR using Power SYBR Green Master Mix (Applied Biosystems, Foster City, CA). 
Our primers were designed by Primer Express software and then validated. The primers that used 
β-actin (NM_007393.3) [Forward-5′-CGTGAAAAGATGACCCAGATCA-3′ and Reverse-5′-
AGCCTGGATGGCTACGTACATG-3′] as a control were PPARγ (NM_011146.3) [Forward-5′-
GCCCACCAACTTCGGAATC-3′ and Reverse-5′-TGCGAGTGGTCTTCCATCAC-3′] and 
ACOX1 (NM_027107.1) [Forward-5′-TCTGGAGATCACGGGCACTT-3′ and Reverse-
5′TTCCAAGCCTCGAAGATGAGTT-3′].  For analysis of PPARα (NM_011144.6) [Forward-
5′CGA TGC TGT CCT CCT TGA TGA-3′ and Reverse-5′-TC GCG TGT GAT AAA GCC 
ATT-3′] and FABP4 (NM_ 024406.2) [Forward-5′-AAACTGGGCGTGGAATTCG-3′ and 
Reverse-5′-GGTTATGATGCTCTTCACCTTCCT-3′], L7A (NM_013721.3) [Forward-5′-
CCTCTACAAGCGGCTCAAAGTC-3′ and Reverse-5′-CCAGGGCCTGGGTGAAC-3′] was 
used as the control gene. Reactions were monitored by an ABI Prism 7900HT (Applied 
Biosystems, Carlsbad, CA).  
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Tissue Carotenoid Extraction  
All carotenoid samples were kept under yellow lights and on ice during the extraction 
procedure. Tissue samples were extracted using the procedure previously described with slight 
modifications (52). Briefly, 5 mL of ethanol containing 0.01% butylated hydroxytoluene (BHT) 
was added to 0.06-0.11g minced liver tissue or 0.2-0.7g adipose tissue. 1 mL 1:1 saturated (1g 
KOH to 1mL water) KOH was added and the samples were vortexed. A polystat model 12050-
00 circulator rocking water bath (Cole Palmer, Court Vernon Hills, IL) at 60⁰C was used to 
saponify the samples for 30 minutes with intervals of vortexing occurring every 10 min. 2 ml of 
distilled water was added and carotenoids were extracted three times with 6 ml of hexane, dried 
under reduced pressure (SpeedVac concentrator, model AES1010, Savant, Milford, MA), and 
then topped with argon gas to prevent carotenoid degradation. For analysis, samples were 
reconstituted in methyl-tert-butyl ether and put into autosampler vials for use on a C30 HPLC 
column (18ºC, 4.6 x 150 mm, 3µm; YMC, Wilmington, NC). A reverse-phase HPLC-PDA 
method was used to analyze the samples (53, 54). All-trans and 5-cis lycopene peaks were 
confirmed and quantified separately where possible and the rest of the cis lycopene peaks were 
quantified but their peak area counts were added together and labeled as “other cis lycopene”. 
Standards for individual carotenoids were used for comparison of elution times and absorption 
spectra.  
Hepatic H&E Staining  
For paraffin sections, livers were fixed in 10% formalin, transferred to ethanol after 24 
hours and processed into paraffin blocks within a week of sacrifice. The embedded tissues were 
cut into 4-μm slices, mounted on slides, and dried in a 60ºC oven. Slides were then stained using 
a standard hematoxylin and eosin (H&E) staining procedure used by the Veterinary Medicine 
 18 
 
Pathology Lab at the University of Illinois-Urbana/Champaign. Representative histologic 
sections of each specimen (8/diet/genotype from the 4 day feeding study) were stained with 
H&E.  
Statistical Analysis  
Lycopene and tomato powder fed animals were statistically analyzed for their carotenoid 
content of the animal tissues. One way ANOVA was used for comparison of each KO genotype 
(CMO-I KO and CMO-II KO) with WT mice by SAS 9.1 (Cary, NC) with α = 0.05. Tomato 
powder-fed KO animals were only compared with WT tomato powder-fed animals and lycopene 
beadlet-fed KO animals were only compared with lycopene beadlet-fed WT animals. Results 
were expressed as means ± SEM. Statistical significance was considered when P ≤0.05. 
Organ weights and body weights were initially analyzed with a 2 x 2 factorial 
arrangement where each knock-out genotype (CMO-I KO, CMO-II KO) was compared to WT 
mice individually. There were no dietary effects seen with this statistical design so carotenoid-
fed (tomato powder and lycopene beadlet) animal body weights and tissue weights, as a percent 
of body weight, were pooled with their respective control diet (AIN-93G or placebo beadlet diet) 
body weights and tissue weights, as a percent of body weight, for each genotype (expect for 
livers in the 30 day study). Following pooling of groups, one way ANOVA was used for 
comparison of each KO genotype (CMO-I KO and CMO-II KO) with WT mice with α = 0.05. 
A 2 x 2 factorial design was used to analyze the hepatic and serum cholesterol, and gene 
expression data. Each knock-out genotype (CMO-I KO, CMO-II KO) was compared to WT mice 
individually. Carotenoid diets were only compared with their respective control diets (lycopene 
beadlet with placebo beadlet or tomato powder with AIN-93 G). Interactions between genotype 
and diet were investigated. All parameters were analyzed by analysis of variance (2-way 
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ANOVA). When it was possible, we blocked for cohort. When assumptions for ANOVA were 
violated, data were transformed by natural log or repeated measures were used. Results were 
expressed as means ± SEM. Statistical significance was considered when P ≤0.05. 
Results 
CMO-I KO mice and CMO-II KO mice differentially accumulate carotenoids 
 There were substantial genotype effects on lycopene accumulation in liver and adipose 
tissue following 30 days of tomato powder or lycopene beadlet feeding. CMO-I KO mice had 
significantly less total lycopene in their livers compared to WT mice when fed either 10% 
tomato powder or lycopene beadlet diets for 30 days (Figures 2&3, Tables 2&3). Tomato 
powder-fed CMO-I KO mice also accumulated less phytoene (PE) in their livers compared to 
WT mice (Figure 2, Table 2). In contrast, CMO-II KO mice had significantly more hepatic all-
trans/5-cis and other cis isomer lycopene with tomato powder feeding and increased total 
lycopene accumulation when fed lycopene beadlet diet compared to WT mice. In the adipose 
tissue of the 30 day study animals, there were similar trends in lycopene accumulation as 
reported for the liver. CMO-II KO mice fed either lycopene beadlets or tomato powder had 
higher adipose total lycopene and all-trans/5-cis lycopene concentrations were significantly 
higher compared to WT mice (Figures 4&5, Tables 4&5). Other cis isomer lycopene 
accumulation was not statistically different between genotypes in the adipose tissue. In the serum 
of lycopene beadlet-fed animals, total lycopene accumulated significantly more in the CMO-I 
KO mice compared to WT mice (Figure 6, Table 6). For CMO-II KO mice, no significant 
differences in lycopene accumulation were noted when comparing WT mice with either 
carotenoid diet groups.   
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 In the 4 day feeding study, lycopene-fed animals showed a similar genotypic carotenoid 
profile as the 30 day feeding study animals. CMO-I KO mice accumulated significantly lower 
levels of all-trans/5-cis lycopene in their livers compared to WT mice (Figure 7, Table 7). Total 
lycopene showed a trend of being higher in CMO-II KO mice and lower in CMO-I KO mice 
compared to their respective WT groups.  
In addition to measuring lycopene, we also measured phytofluene (PF), PE and β-
carotene (BC) in mouse tissues. BC was present in our tomato powder diet and in our liver 
tissues but it was at levels that were not quantifiable (data not shown). We were able to quantify 
PF and PE in the livers of our 30 day and 4 day studies but we could not identify PE and PF in 
the serum or the adipose tissue in all animals fed tomato powder diets. When looking at the PE 
peaks in our serum and adipose tissue we noticed a peak that had a similar retention time to PE 
and a maximum absorbance was similar to PE. However, the spectra did not show a carotenoid 
spectral fine structure expected of PE (Figure 8). These peaks were considered pseudo-PE and 
were not included in analysis.  
CMO-II KO mice have reduced body weights  
All mice were provided food and water ab libitum but feed intake was not measured. 
Prior to the 30 day experimental diet-feeding, the CMO-II KO mice were significantly smaller (P 
<0.001) than WT mice and gained significantly less weight during the study (2.3 ± 0.4 g vs 4.8 ± 
0.4 g) (P <0.001). At the completion of the study there were no differences in body weight or 
organ weight (with the exception of liver) as a percent of body weight between diets in each 
genotype, so each carotenoid-containing diet was pooled with its control diet (tomato powder 
and AIN-93G, lycopene beadlet and placebo beadlet; results portrayed as “pooled” in Table 8 
and 9). CMO-II KO mice were significantly smaller than WT mice (Table 8). CMO-II KO mice 
 21 
 
were also smaller at the beginning (P <0.001) and upon completion of the 4 day study compared 
to WT mice (Table 9). CMO-I KO mice were not significantly different in body weight or 
change in body weight compared to WT mice in either study.  
We analyzed the visceral adipose weights (gonadal and perirenal adipose pads) of mice in 
our 30 day and 4 day studies. Visceral adipose weights, as a percent of body weight, were 
smaller in the CMO-II KO mice from the 30 day study and larger in the CMO-I KO from the 4 
day feeding study mice compared to WT mice (Tables 8&9). In the 30 day study, the CMO-II 
KO mice had significantly larger livers, spleens and kidneys, as a percent body weight, 
compared to WT mice (Table 8). The livers, spleens and kidneys of the CMO-I KO mice were 
not significantly different from WT mice in weights, as a percent body weight, in the 30 day 
study. Conversely, in the 4 day study CMO-I KO mice had significantly smaller kidneys, as a 
percent body weight compared to WT mice (Table 9).  CMO-II KO mice had significantly larger 
spleens, as percent body weight, when fed either the tomato powder or AIN-93 G diets compared 
to WT mice. Livers in the 4 day study were not different in sizes between genotypes.  
In addition to a genotype effect in CMO-II KO mouse 30 day study livers there was a diet 
effect. Lycopene beadlet feeding significantly decreased the liver weight as a percent body 
weight in both CMO-II KO (lycopene 3.45 ± 0.09 % body weight; placebo 3.87± 0.09 % body 
weight and WT mice (lycopene 3.35 ± 0.09 % body weight compared to placebo 3.45± 0.09 % 
body weight; P 0.006) (data not shown).   
KO mice have reduced reproductive organ weights 
 In both the 30 day and 4 day study, CMO-I KO mice and CMO-II KO mice had 
significantly smaller uteri as a percent of body weight compared to WT mice (Tables 8&9). Also 
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in the 30 day study, CMO-I KO mice had significantly smaller ovaries as a percent of body 
weight compared to WT mice but there was no modulation of diet on these weights (Table 9).  
KO mice have greater accumulation of hepatic lipids 
 We analyzed lipid accumulation in the livers of our 30 day and 4 day-fed animals. For the 
most part, CMO-I KO mice and CMO-II KO mice accumulated more hepatic lipids compared to 
the appropriate WT group (Tables 10, 11, 12, 13). CMO-I KO mice fed AIN-93 G control diet 
and tomato powder were did not different from WT mice in liver lipid accumulation. 
CMO-I KO mice have an increased incidence of minimal hepatic lipidosis 
 We analyzed the H&E stained liver slides from the 4 day study. Only CMO-I KO mice 
had signs of minimal hepatic lipidosis in 2 of the 8 representative slides (Figure 9). There were 
no differences between dietary groups.  
CMO-II KO mice have altered cholesterol accumulation 
 We measured liver and serum total cholesterol accumulation in our 30 day and 4 day-fed 
animals. There was no difference in hepatic cholesterol due to diet or genotype in our 30 day-fed 
animals. In the 4 day feeding study, CMO-II KO mice fed placebo beadlet and lycopene beadlet 
diets had higher levels of hepatic total cholesterol compared to WT mice (Table 14).  
 There were significant differences in serum total cholesterol in our animals. CMO-I KO 
mice had lower serum cholesterol levels than WT animals in the 30 day study animals fed either 
tomato powder or AIN-93G (Table 15). There was an interaction between the CMO-I KO 
genotype and lycopene beadlet feeding in the 4 day study in serum cholesterol (Table 17). 
CMO-II KO mice in the 30 day and 4 day feeding studies had significantly reduced levels of 
serum cholesterol compared to WT mice (Tables 16&18).  
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Tomato powder-feeding modulates expression of PPARγ and its target gene 
 We measured mRNA expression of PPARγ and its target gene in the adipose tissue, 
FABP4, in the 30 day feeding animals. Tomato powder increased hepatic PPARγ expression in 
both WT and CMO-II KO mice (diet effect P-value 0.006) (Figure 10a). In contrast, in the 
CMO-II KO mice fed placebo beadlet and lycopene beadlet diets, there was a decrease in hepatic 
PPARγ mRNA expression compared to WT mice fed these diets (genotype effect P-value 0.046) 
(Figure 10b). In the CMO-I KO mouse livers there was a trend of tomato powder increasing 
PPARγ mRNA expression (data not shown). In the adipose tissue, the CMO-II KO mice had 
increased PPARγ expression compared to WT mice independent of diet (genotype effect P-value 
<0.001 for both groups) (Figures 11a&11b). Lycopene was shown to increase PPARγ mRNA 
expression in WT mice and decrease its expression in CMO-I KO mice (diet effect P-value 
0.023) (Figure 12). We also measured FABP4 in the adipose tissue of these animals and found 
that CMO-II KO mice had decreased FABP4 mRNA expression when fed AIN-93G and tomato 
powder diets (Figure 13). Lycopene decreased FABP4 mRNA expression in CMO-I KO mice 
and WT mice (Figure 14).  
Tomato powder-feeding increases PPARα expression in CMO-I KO mice 
 We measured PPARα mRNA expression in the livers of our 30 day feeding mice. 
Tomato powder increased PPARα mRNA expression in both CMO-I KO and WT mice (Figure 
15). There was a trend of tomato powder increasing PPARα mRNA in CMO-II KO mice (data 
not shown).  
Discussion 
Carotenoid consumption has been associated with the reduction of many chronic diseases 
such as heart disease (55) and cancers of the lung, breast, prostate, cervix and ovary, to name a 
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few (2). Provitamin A carotenoid consumption helps to alleviate vitamin A deficiency symptoms 
which can lead to night blindness, impaired immune function, and numerous other negative 
health outcomes (1). Mice lacking CMO-I and CMO-II, enzymes responsible for cleaving 
carotenoids centrally (4) and eccentrically, respectively (8), have been used as models to 
investigate carotenoids and their metabolites. These knock-out mouse models show that there are 
differences in tissue accumulation of carotenoids and their metabolites in these two genotypes 
(23, 24).  
We were interested in investigating different measures of lipid status such as hepatic lipid 
deposition and lipid metabolism-related genes in our CMO-I KO and CMO-II KO mice. CMO-I 
KO mice have been found to have elevated levels of hepatic lipids, serum free fatty acids and 
triglycerides, and genes involved in lipid metabolism regardless of dietary carotenoids, 
indicating these mice have a disruption in lipid metabolism (47). It has also been suggested that 
development of hepatic steatosis, a decrease in the expression of genes involved in fatty acid 
metabolism and an increase in triglyceride concentrations may be related to a lack in CMO-I (1, 
47). We wanted to investigate lipid metabolism in older female mice because lipid alterations 
appeared to be more pronounced in the female mice (47). We also wanted to determine if tomato 
powder or lycopene modulated these changes. We fed 25-29 week old CMO-I KO mice, CMO-II 
KO mice and WT mice carotenoid-containing diets and their respective controls for either 30 or 
4 days. We also investigated if a short term (4 day) carotenoid feeding would demonstrate 
similar changes in lipid deposition and gene regulation compared to a longer 30 day feeding in 
our mice.  
Our lab has previously shown the carotenoid distribution of lycopene and tomato powder-
fed CMO-I KO and CMO-II KO male mice (23) and lycopene and β-carotene-fed CMO-I KO 
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male and female mice (24). As expected, in our current study we found that female CMO-I KO 
mice compared to WT mice, accumulated significantly lower levels of lycopene from lycopene 
beadlet diet and the tomato powder diet in their livers regardless of the duration of feeding.  Our 
findings also support the role of CMO-II as a key enzyme in the metabolism of lycopene because 
we found that CMO-II KO mice fed either lycopene or tomato powder to have significantly 
higher levels of total lycopene in their livers and adipose compared to their respective WT 
controls. These results support previous evidence that CMO-I KO mice have
 
upregulated 
expression of CMO-II in some tissues suggesting that there is a compensatory mechanism 
involved with these enzymes (23). To our surprise, we found that the serum lycopene 
accumulation did not follow the same patterns as the liver or the adipose tissue lycopene 
accumulation. CMO-I KO mice fed lycopene beadlet diet had enhanced serum accumulation of 
lycopene compared to their lycopene beadlet-fed WT controls. We did not measure lycopene 
concentrations in the serum of our 4 day animals. In a previous study from our lab, both male 
and female CMO-I KO mice were fed lycopene beadlet diet, there were no significant difference 
in serum total lycopene accumulation compared to WT lycopene beadlet diet-fed animals after 
60 days of feeding (24). Other than the serum lycopene results from the current work, our 
laboratory has seen a consistently higher tissue accumulation of lycopene when either tomato 
powder or lycopene beadlet diet is fed to CMO-II KO mice and a lower distribution of lycopene 
in CMO-I KO mice (23,24).  
In order to determine differences in body weight and organ weights we monitored animal 
weight gain throughout the studies and weighed the organs at the termination of the study. CMO-
I KO mice were not different from WT mice in body weight at the end of either the 30 day or the 
4 day studies. These findings contradict previous research which found CMO-I KO mice to be 
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heavier than WT mice (24, 47). The differences between our mice and the mice in these other 
studies were that our mice were not fed a high fat diet. This suggests that under a high fat diet 
(16.7% dry weight and 30% w/w)  the CMO-I KO genotype is more vulnerable to enhanced lipid 
accumulation and weight gain than WT mice, but if the mice are kept on a lower fat (7-10% of 
dry weight) diet their body weights and tissue lipids will be more similar to WT mice. We 
hypothesized that our CMO-II KO mice would not be different in body weight at the completion 
of our feeding study because of previous work from our lab with male mice fed lower fat diets 
(23).  
Conversely, we found our CMO-II KO mice weighed less than their respective WT mice 
at the completion of both the 30 day and 4 day studies. The mice in Ford study were younger (9-
12 weeks old) male mice, whereas our mice were all older (30-35 weeks old) female mice (23). 
One conclusion from this data is that, when female CMO-I KO mice are fed a standard level of 
fat in their diets they do not differ from WT mice in body weight. Also, we conclude that female 
CMO-II KO mice are smaller than WT mice and that the presence of carotenoids in the diet does 
not overcome the difference.  
Contrary to our body weight data, we found reproductive organ weights, as a percent of 
body weight, to differ by genotype which has been demonstrated, in part, in the literature. 
Previous findings from our lab found CMO-I KO mice to have smaller uteri, as a percent of body 
weight, regardless of diet compared to WT mice (24).  We found both CMO-I KO mice and 
CMO-II KO mice uteri to be smaller than their respective WT controls. This is of interest to us 
because we found the reproductive capacity of our breeding colonies of CMO-II KO mice to be 
decreased (average~2 pups/litter) compared to CMO-I KO mice (average~5 pups/litter) fed a 
standard chow diet. Although CMO-I KO mice did have increased litter sizes compared to 
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CMO-II KO mice, the litter sizes are still smaller compared to WT mice (mean litter size 6.2 
according to Jackson Laboratory).  
In addition to smaller uteri weights, we found that the ovary weights, as a percent of body 
weight, were lower in the 30 day CMO-I KO mice study animals compared to WT mice. 
Considering this novel finding of decreased ovary weights in CMO-I KO mice, and the 
decreased uteri weight data in both CMO-I KO and CMO-II KO mice, it would be interesting to 
investigate the hormonal differences between these mice and WT mice in order to determine if 
the reproductive differences in these genotypes were due to altered hormone balances.   
In the 30 day study, CMO-II KO mice had significantly larger livers, spleens and kidneys 
as a percent body weight compared to WT mice. These results were not generally seen in the 4 
day study. Additionally, in the 30 day study dietary lycopene resulted in decreased liver weights 
in both CMO-II KO mice and WT mice. No dietary effects were seen in any other tissues in 
either of the studies. In the 4 day study kidney weights, as percent body weight, were 
significantly lower in CMO-I KO mice compared to WT mice. The differences in organ weights, 
as percent body weight, were generally independent of carotenoid feeding and demonstrate the 
genotypic differences between the two strains of KO mice compared to WT mice. This further 
supports the idea that carotenoid cleavage enzymes may have a number of roles in tissues 
beyond those related to carotenoid metabolism.    
We next wanted to determine how tomato powder and lycopene beadlet diets might 
influence lipid accumulation in the livers of our KO mice. We hypothesized that our CMO-I KO 
mice would develop hepatic steatosis independently of diet, in line with the results reported by 
Hessel et. al., who found that CMO-I KO mice developed fatty liver regardless of vitamin A 
status of the diet (47). Our findings fell in line with these results, but hepatic lipid alterations 
 28 
 
were more modest. Female CMO-I KO mice had a greater accumulation of hepatic lipids 
compared to their respective WT controls. However, when histology was done on representative 
liver samples, we saw that 75% of livers were normal and 25% of the samples in the CMO-I KO 
mouse group only showed minimal hepatic lipidosis. One of the 2 livers that showed signs of 
minimal hepatic lipidosis was from a carotenoid-fed animal and the other was from a control 
diet-fed animal. These findings support the idea that carotenoids in the diet do not significantly 
impact lipid deposition and steatosis in the livers of CMO-I KO mice fed lower fat diets. 
Interestingly, the same group that reported hepatic steatosis in their CMO-I KO mice also 
reported hepatic steatosis in CMO-II KO mice fed lower fat diets supplemented with zeaxanthan 
(10). Male and female CMO-II KO mice, heterozygous and homozygous CMO-II KO mice fed 
zeaxanthan, but not chow-fed homozygous CMO-II KO mice. In our CMO-II KO mice we also 
found a modest increase in hepatic lipid deposition, but H&E staining did not revealed evidence 
of hepatic steatosis. Also, our CMO-II KO mice accumulated hepatic lipids irrespective of 
carotenoid-containing diets. One explanation for the differences of current findings with those of 
Amengual et al., is that the CMO-II KO mice in our study received lycopene (0.1g lycopene/kg 
diet), not zeaxanthan. The mice in the Amengual et al. report were also both male and female, 13 
weeks old at sacrifice, and fed a 0.05 mg/g zeaxanthan supplemented vitamin A-deficient 
(vitamin A levels not provided) experimental diets for 8 weeks. Of greater importance may be 
that Amengual and coworkers (10) fed a vitamin A-deficient diet for 8 weeks which would 
render these animals close to outright vitamin A deficiency.   
Our lab previously showed that CMO-I KO mice fed high fat and cholesterol-containing 
diets with lycopene had significantly lower serum cholesterol levels when compared to CMO-I 
KO mice fed cholesterol diet without lycopene (24). Palozza et al. reported that when lycopene 
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was administered to a variety of human cells in culture; there was a dose dependent decrease in 
total intracellular cholesterol content in vitro along with a reduction of the expression of HMG-
CoA reductase (56). Based on these experiments we wanted to investigate both the serum and 
hepatic total cholesterol levels in our carotenoid cleavage enzyme knock-out mice. There were 
no dietary effects on hepatic cholesterol accumulation in our mice but we did find that when 
CMO-II KO mice were fed placebo and lycopene beadlet diets they had increased total 
cholesterol levels. In the 30 day feeding study CMO-I KO and CMO-II KO mice fed AIN-93G 
and tomato powder diets had lower levels of serum cholesterol compared to WT mice. CMO-II 
KO mice also had lower levels of serum cholesterol in the 4 day study. There was also a dietary 
effect in the 30 day study that showed an increase in serum cholesterol in WT mice with 
lycopene feeding but a decrease in CMO-II KO mouse serum cholesterol.  
In order to determine potential effects of tomato powder and lycopene feeding on genes 
involved in lipid metabolism we performed RT-PCR on our 30 day liver and adipose samples. 
We were specifically interested in the PPARs, especially PPAR-γ because PPARγ and RXRα 
agonists increased the rate of gene expression of CMO-I by forming a heterodimer in the 
promoter region of CMO-I thus increasing transcription of the CMO-I gene (41). Also, the 
peroxisome proliferator response element (PPRE) site is located in the CMO-I promoter. This 
information is important for understanding the role of this carotenoid cleavage enzyme in lipid 
metabolism.  
In our study we found that tomato powder feeding increased hepatic PPARγ mRNA 
expression in the CMO-II KO and WT mice and there was a trend for an increase expression in 
CMO-I KO mice. These effects caused by tomato powder were not seen in the adipose tissue. In 
addition, we found PPARγ expression to be increased in the adipose of CMO-II KO mice, but to 
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our surprise, FABP4, a PPARγ target gene in the adipose, was decreased in these same mice. We 
have no explanations for these findings.  
Another interesting finding from our mRNA expression data was that dietary lycopene 
modulated PPARγ mRNA expression differently compared tomato powder feeding. Feeding a 
lycopene beadlet diet decreased mRNA expression of both PPARγ and FABP4 in the adipose of 
CMO-I KO mice. These results are similar to those in a rat study from our lab, where they found 
that lycopene beadlet diets decreased mRNA expression of PPARγ and its target gene FABP3 in 
the rat adrenals and kidneys (46). It was hypothesized that CMO-II activity on lycopene may be 
what is causing this decrease in expression of PPARγ and CMO-I (47). This hypothesis is based 
on data that showed that a CMO-II short chain cleavage product of β-carotene, apocarotenal 14 
(apo14), repressed known PPARγ, PPARα and RXRα transcriptional responses by their 
respective agonists (57). It is therefore possible that asymmetric cleavage of lycopene would also 
produce lycopenals or their metabolic products that could repress PPARγ-regulated target genes, 
such as FABP4. Additionally, it is possible that other cleavage products of carotenoids, and not 
just asymmetric cleavage products, could have regulatory effects on PPARs and RXRα 
transcriptional responses. This hypothesis could provide some explanation as to why FABP4 was 
decreased in the adipose tissue of multiple carotenoid-containing (PE, PF and β-carotene) tomato 
powder-fed CMO-II KO mice (57). 
 We were also interested in looking at PPARα and its target gene ACOX1. We found that 
tomato powder significantly increased the mRNA expression of PPARα in the livers of CMO-I 
KO mice. Hessel et al. fed a vitamin A sufficient standard diet to both male and female mice and 
did not find any differences in liver mRNA expression of PPARα between CMO-I KO and WT 
(47). In contrast, these researchers found hepatic ACOX1 mRNA expression to be upregulated in 
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CMO-I KO mice compared to WT mice. We did not see any differences in either hepatic or 
adipose mRNA expression of ACOX1. As seen in the PPARγ and FABP4 results from the 
adipose of CMO-I KO mice, the mRNA expression of the regulator gene does not always 
influence the mRNA expression of the target gene. Protein levels of PPARα and ACOX1 should 
also be analyzed in order to determine if levels of these proteins can be influenced by tomato 
powder. If the protein levels of ACOX1 are seen to be decreased, as seen in Hessel et al. (47), 
investigation into apo14 levels in the liver would interesting to measure. 
The data presented provide a description of alterations in lipid deposition and organ 
weights in female CMO-I KO mice and CMO-II KO mice. These results suggest that the lack of 
a carotenoid cleavage enzyme in itself has more influence on altering lipids than the addition of 
tomato carotenoids in the diet. In addition, the data on carotenoid accumulation in female CMO-
II KO mice fed lycopene and tomato powder-containing diets is novel and has not been 
published previously and it is important to understand how these animals accumulate these 
carotenoids.  
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Figures 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study Design. n=10/genotype/diet/study; WT (C57BL/6Jx129x1/SvJ) 
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Figure 2: Carotenoid accumulation in the livers of tomato powder-fed 30 day study animals;  
* Indicates significantly different from WT; n=6-10/genotype  
 
  
Figure 3: Carotenoid accumulation in the livers of lycopene beadlet-fed 30 day study animals;  
* Indicates significantly different from WT; n=6-10/genotype 
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Figure 4: Carotenoid accumulation in the gonadal adipose of tomato powder-fed 30 day study 
animals; * Indicates significantly different from WT; n=8/genotype 
 
  
Figure 5: Carotenoid accumulation in the gonadal adipose of lycopene beadlet-fed 30 day study 
animals; * Indicates significantly different from WT; n=7-8/genotype  
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Figure 6: Carotenoid accumulation in the serum of lycopene beadlet-fed 30 day study animals;  
* Indicates significantly different from WT; n=5-6/genotype 
 
  
Figure 7: Carotenoid accumulation in the liver of lycopene beadlet-fed 4 day study animals; 
*Indicates significantly different from WT; n=6-7/genotype 
 
0
100
200
300
400
500
600
700
800
Total Lycopene All trans/5 cis cis isomers
C
ar
o
te
n
o
id
 C
o
n
ce
n
tr
at
io
n
 (
n
M
o
l/
L
) 
WT
CMO-I KO
CMO-II KO
* 
* 
0
5
10
15
20
25
Total Lycopene All trans/5 cis cis isomers
C
ar
o
te
n
o
id
 C
o
n
ce
n
tr
at
io
n
 (
n
M
o
l/
g
) 
WT
CMO-I KO
CMO-II KO
* 
 36 
 
A.        B. 
    
C. 
  
Figure 8: Comparison of PE and pseudo PE spectra. A) Adipose pseudo PE peak in CMO-II KO 
mouse fed tomato powder for 4 days B) Standard PE peak C) Liver PE peak in a CMO-II KO 
mouse fed tomato powder for 30 days 
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A.          B. 
 
 
 
 
 
C.  
         
Figure 9: H&E stained CMO-I KO liver slides compared to a WT slide. A) CMO-I KO mouse 
fed tomato powder for 4 days, minimal lipidosis B) CMO-I KO mouse fed placebo beadlet diet 
for 4 days, minimal lipidosis C) WT mouse fed AIN-93G diet for 11 days, normal liver 
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Figure 10a: mRNA expression of PPARγ in the liver of CMO-II KO and WT mice; * Indicates 
significantly different from control diet; n=4-8/genotype/diet 
 
 
Figure 10b: mRNA expression of PPARγ in the liver of CMO-II KO and WT mice; * Indicates 
significantly different from WT; n=5-6/genotype/diet 
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Figure 11a: mRNA expression of PPARγ in the adipose tissue of CMO-II KO and WT mice; * 
Indicates significantly different from WT; n=7-9/genotype/diet 
 
  
Figure 11b: mRNA expression of PPARγ in the adipose tissue of CMO-II KO and WT mice; * 
Indicates significantly different from WT; n=6-9/genotype/diet  
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Figure 12: mRNA expression of PPARγ in the adipose tissue of CMO-I KO and WT mice; * 
Indicates significantly different from control diet; n=8-9/genotype/diet  
 
  
Figure 13: mRNA expression of FABP4 in the adipose tissue of CMO-II KO and WT mice; * 
Indicates significantly different from WT; n=7-9/genotype/diet  
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Figure 14: mRNA expression of FABP4 in the adipose tissue of CMO-I KO and WT mice; * 
Indicates significantly different from control diet; n=7-9/genotype/diet 
 
  
Figure 15: mRNA expression of PPARα in the liver of CMO-I KO and WT mice; * Indicates 
significantly different from control diet; n=7-9/genotype/diet 
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Tables 
Table 1: Diet composition of 30 day and 4 day studies. 
Ingredients 
AIN-93G  10% Tomato 
Powder
A,B 
Placebo 
Beadlet  
10% Lycopene 
Beadlet
C,D 
(g/kg diet) 
Cornstarch 397.5 331.5 397.5 397.5 
Casein 200 187.5 200 200 
Maltodextrin 102 132 102 102 
Sucrose 100 100 100 100 
Fiber 50 34 50 50 
Mineral Mix 35 35 35 35 
Vitamin Mix (Low Vitamin A) 10 10 10 10 
L-cystine 3 3 3 3 
Choline Bitartrate 2.5 2.5 2.5 2.5 
Soybean Oil 100 65 100 100 
Tomato Powder 0 100 0 0 
Lycopene Beadlets 0 0 0 1.0 
Placebo Beadlets 0 0 1.0 0 
A
 The 30 day study contained: 40 ± 5 nMol/g diet cis isomer lycopene; 140 ± 22 nMol/g diet 
all-trans/5-cis lycopene; 8 ± 1.3 nMol/g diet of phytoene (PE); 6 ± 0.9 nMol/g diet phytofluene 
(PF); 2 ± 0.3 nMol/g β-carotene (BC) B The 4 day study contained: 46 ± 0.6 nMol/g diet cis 
isomer lycopene; 188 ± 12 nMol/g diet all-trans/5-cis lycopene; 12 ± 0.02 nMol/g diet of PE; 7 
± 0.7 nMol/g diet PF; 2 ± 0.1 nMol/g diet BC 
C
 The 30 day study contained 22 ± 2 nMol/g diet 
cis isomer lycopene; 129 ± 4.7 nMol/g diet all-trans/5-cis lycopene 
D
 The 4 day study 
contained 28 ± 2 nMol/g diet cis isomer lycopene; 148 ± 19 nMol/g diet all-trans/5-cis 
lycopene 
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Table 2: Carotenoid accumulation in the livers of tomato powder-fed 30 day study 
animals. 
* Indicates significantly different from WT; bolded P-value indicates significant of <0.05; 
n=6-10/genotype; **P-values represent comparison between WT mice and each KO mouse 
genotype individually 
   
 
Table 3: Carotenoid accumulation in the livers of lycopene beadlet-fed 30 day study 
animals. 
Carotenoid 
WT CMO-I KO CMO-II KO P-value** 
nMol/g weight ± SEM CMO-I KO CMO-II KO 
Total lycopene 46.3 ± 5.9 11.2 ± 1.1* 85.4 ± 12.6* <0.001 0.02 
All trans/ 5 cis 27.7 ± 4.5 5.5 ± 0.7* 55.6 ± 9.1* <0.001 0.02 
cis isomers 16.8 ± 2.1 6.3 ± 0.5* 29.7 ± 3.8* <0.001 0.02 
* Indicates significantly different from WT; bolded P-value indicates significant of <0.05; n=6-
10/genotype; **P-values represent comparison between WT mice and each KO mouse 
genotype individually 
 
 
  
Table 4: Carotenoid accumulation in the gonadal adipose of tomato powder-fed 30 day 
study animals. 
Carotenoid 
WT CMO-I KO CMO-II KO P-value** 
nMol/g weight ± SEM CMO-I KO CMO-II KO 
Total lycopene 0.21 ± 0.03 0.20 ± 0.03 0.40 ± 0.06* 0.71 0.02 
All-trans/ 5-cis 0.12 ± 0.02 0.11 ± 0.02 0.21 ± 0.03* 0.92 0.02 
cis isomers 0.10 ± 0.02 0.08 ± 0.01 0.19 ± 0.04 0.51 0.07 
* Indicates significantly different from WT; bolded P-value indicates significant of <0.05; 
n=8/genotype; **P-values represent comparison between WT mice and each KO mouse 
genotype individually 
  
Carotenoid 
WT CMO-I KO CMO-II KO P-value** 
nMol/g weight ± SEM CMO-I KO CMO-II KO 
Total lycopene 64.5 ± 9.5 14.8 ± 1.9* 112 ± 22.9 <0.001 0.41 
All trans/5cis 45.2 ± 7.7 7.5 ± 1.3* 75.0 ± 15.2* 0.002 0.04 
Cis isomers 22.1 ± 2.2 7.4 ± 0.8* 38.3 ± 7.1* <0.001 0.04 
PE 7.8 ± 1.7 7.9 ± 1.3* 3.7 ± 0.6 0.03 0.80 
PF 5.6 ± 0.7 3.0 ± 0.7 6.3 ± 1.1 0.28 0.21 
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Table 5: Carotenoid accumulation in the gonadal adipose of lycopene beadlet-fed 30 day 
study animals. 
Carotenoid 
WT CMO-I KO CMO-II KO P-value** 
nMol/g weight ± SEM CMO-I KO CMO-II KO 
Total lycopene 0.17 ± 0.02 0.18 ± 0.02 0.26 ± 0.03* 0.886 0.03 
All trans/ 5 cis 0.11 ± 0.01 0.09 ± 0.01 0.15 ± 0.02* 0.226 0.01 
cis isomers 0.08 ± 0.01 0.07 ± 0.01 0.11 ± 0.02 0.446 0.10 
* Indicates significantly different from WT; bolded P-value indicates significant of <0.05; 
n=7-8/genotype; **P-values represent comparison between WT mice and each KO mouse 
genotype individually 
 
 
 
Table 6: Carotenoid accumulation in the serum of lycopene beadlet-fed 30 day study 
animals. 
Carotenoid 
WT CMO-I KO CMO-II KO P-value** 
nMol/L weight ± SEM CMO-I KO CMO-II KO 
Total lycopene 415 ± 21.7 594 ± 80.4* 408 ± 17.2 0.04 0.81 
All-trans/5-cis 247 ± 21.0 421 ± 64.6* 237 ± 10.0 0.02 0.65 
cis isomers 168 ± 5.2 173 ± 16.4 172 ± 9.3 0.74 0.72 
* Indicates significantly different from WT; bolded P-value indicates significant of <0.05; 
n=5-6/genotype; **P-values represent comparison between WT mice and each KO mouse 
genotype individually 
 
 
 
Table 7: Carotenoid accumulation in the liver of lycopene beadlet-fed 4 day study 
animals. 
Carotenoid 
WT CMO-I KO CMO-II KO P-value** 
nMol/g weight ± SEM CMO-I KO CMO-II KO 
Total lycopene 7.4 ± 1.6 3.8 ± 1.9 17.7 ± 5.6 0.17 0.22 
All trans/5 cis 3.8 ± 1.0 1.5 ± 0.4* 9.0 ± 4.0 0.02 0.10 
cis isomers 3.4 ± 0.7 1.9 ± 0.3 5.1 ± 1.6 0.10 0.30 
* Indicates significantly different from WT; bolded P-value indicates significant of <0.05; 
n=6-7/genotype; **P-values represent comparison between WT mice and each KO mouse 
genotype individually 
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Table 8: Body and organ weights of the 30 day feeding study. 
Treatment WT CMO-I KO CMO-II KO 
P-value** 
CMO-I KO CMO-II KO 
Body Weight (g ± SEM) 
TP + AIN-93G
A
 30.1 ± 1.1 30.9 ± 1.5 25.4 ± 2.3* 0.59 <0.001 
LYC + 
Placebo
B 30.7 ± 0.9 32.1 ± 1.2 26.1 ± 0.8* 0.23 <0.001 
Visceral Adipose (weight as a % of body weight) 
TP + AIN-93G
A
 5.4 ± 0.6 5.0 ± 0.6 4.1 ± 0.5 0.47 0.02 
LYC + 
Placebo
B
 
5.2 ± 0.5 5.9 ± 0.6 4.0 ± 0.6* 0.19 0.002 
Uterus (weight as a % of body weight) 
TP + AIN-93G
A
 0.6 ± 0.05 0.3 ± 0.05* 0.4 ± 0.05* <0.001 0.005 
LYC + 
Placebo
B
 
0.6 ± 0.05 0.3 ± 0.05* 0.4 ± 0.05* <0.001 <0.001 
Ovaries (weight as a % of body weight) 
TP + AIN-93G
A
 0.06 ± 0.006 0.04 ± 0.006* 0.06 ± 0.007 0.008 0.50 
LYC + 
Placebo
B
 
0.06 ± 0.006 0.05 ± 0.006 0.06 ± 0.006 0.10 0.78 
Liver (weight as a % of body weight) 
TP + AIN-93G
A
 3.3 ± 0.07 3.4 ± 0.08 3.8 ± 0.06 0.45 <0.001 
LYC + 
Placebo
B
 
3.4 ± 0.07 3.4 ± 0.07 3.7 ± 0.06 0.96 0.006
#
 
Kidney (weight as a % of body weight) 
TP + AIN-93G
A
 0.96 ± 0.02 0.92 ± 0.02 1.03 ± 0.01 0.22 0.002 
LYC + 
Placebo
B
 
0.97 ± 0.03 0.90 ± 0.03 1.03 ± 0.02 0.07 0.008 
Spleen (weight as a % of body weight) 
TP + AIN-93G
A
 0.31 ± 0.02 0.31 ± 0.02 0.36 ± 0.01 0.57 <0.001 
LYC + 
Placebo
B
 
0.28 ± 0.02 0.31 ± 0.02 0.36 ± 0.01 0.79 <0.001 
A
 TP + AIN-93G= tomato powder and AIN-93G-fed animals; 
B
LYC + Placebo= lycopene 
beadlet and Placebo beadlet-fed animals; * Indicates significantly different from WT; **P-
values represent comparison between WT mice and each KO mouse genotype individually;
#
 
signifies a diet effect was seen in addition to genotype; n=20-22/genotype/treatment 
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Table 9: Body and organ weights of the 4 day feeding study. 
Treatment WT CMO-I KO CMO-II KO 
P-value** 
CMO-I KO CMO-II KO 
Body Weight (g ± SEM) 
TP + AIN-93G
A
 27.2 ± 0.7 29.3 ± 0.7 24.2 ± 0.8* 0.59 <0.001 
LYC + Placebo
B 28.0 ± 0.9 29.7 ± 1.2 23.3 ± 0.7* 0.23 <0.001 
Visceral Adipose (weight as a % of body weight) 
TP + AIN-93G
A
 3.0 ± 0.4 4.2 ± 0.4* 2.8 ± 0.4 0.03 0.99 
LYC + Placebo
B
 3.5 ± 0.3 4.0 ± 0.3 2.9 ± 0.3 0.30 0.25 
Uterus (weight as a % of body weight) 
TP + AIN-93G
A
 0.76 ± 0.05 0.3 ± 0.05*
 
0.41 ± 0.06*
 
<0.001 <0.001 
LYC + Placebo
B
 0.60 ± 0.04 0.4 ± 0.04*
 
0.52 ± 0.04
 
<0.001 0.18 
Ovaries (weight as a % of body weight) 
TP + AIN-93G
A
 0.08 ± 0.01
 
0.04 ± 0.01*
 
0.06 ± 0.01
 
<0.001 0.92 
LYC + Placebo
B
 0.07 ± 0.004 0.06 ± 0.007*
 
0.07 ± 0.004*
 
<0.001 0.01 
Liver (weight as a % of body weight) 
TP + AIN-93G
A
 3.6 ± 0.09 3.7 ± 0.09 3.8 ± 0.06 0.37 0.18 
LYC + Placebo
B
 3.6 ± 0.08 3.7 ± 0.08 3.6 ± 0.09 0.41 0.67 
Kidney (weight as a % of body weight) 
TP + AIN-93G
A
 1.1 ± 0.02 1.0 ± 0.02 1.1 ± 0.01 0.002 0.59 
LYC + Placebo
B
 1.1 ± 0.02 0.97 ± 0.02 1.0 ± 0.02 0.004 0.43 
Spleen (weight as a % of body weight) 
TP + AIN-93G
A
 0.30 ± 0.02 0.29 ± 0.02 0.38 ± 0.02 0.49 0.003 
LYC + Placebo
B
 0.30 ± 0.01 0.28 ± 0.01 0.34 ± 0.02 0.52 0.14 
A
 TP + AIN-93G= tomato powder and AIN-93G-fed animals; 
B
LYC + Placebo= lycopene 
beadlet and placebo beadlet-fed animals; * Indicates significantly different from WT; **P-
values represent comparison between WT mice and each KO mouse genotype individually; 
n=20-22/genotype/treatment 
 
 
 
 
 
 
 
 
 
 47 
 
Table 10: Hepatic lipid accumulation in 30 day fed CMO-I KO mice compared to WT 
mice
1
. 
Diet WT CMO-I KO 
P-value 
Genotype Diet Interaction 
AIN-93 G 65.9 ± 4.4 64.6 ± 5.2 
0.43 0.68 0.40 
Tomato Powder 58.2 ± 2.9 67.9 ± 5.8 
Placebo Beadlet 61.0 ± 3.6 76.1 ± 4.9 
<0.05 0.17 0.52 
Lycopene Beadlet 58.3 ± 3.6 68.0 ± 6.3 
1
 Weights are represented as mg lipid/g liver; n=9-11/genotype/diet 
 
 
Table 11: Hepatic lipid accumulation in 30 day fed CMO-II KO mice compared to WT 
mice
1
. 
Diet WT CMO-II KO 
P-value 
Genotype Diet Interaction 
AIN-93 G 65.9 ± 4.4 90.2 ± 7.7 
<0.001 0.16 0.46 
Tomato Powder 58.2 ± 2.9 80.3 ± 9.9 
Placebo Beadlet 61.0 ± 3.6 90.2 ± 10.5 
<0.001 0.08 0.32 
Lycopene Beadlet 58.3 ± 3.6 74.8 ± 7.0 
1
 Weights are represented as mg lipid/g liver; n=9-11/genotype/diet 
 
 
Table 12: Hepatic lipid accumulation in 4 day fed CMO-I KO mice compared to WT 
mice
1
. 
Diet WT CMO-I KO 
P-value 
Genotype Diet Interaction 
AIN-93 G 53.3 ± 3.4 62.0 ± 5.4 
0.01 0.49 0.27 
Tomato Powder 47.5 ± 1.5 63.8 ± 5.0 
Placebo Beadlet 48.8 ± 2.2 61.8 ± 3.5 
0.01 0.61 0.24 
Lycopene Beadlet 51.1 ± 2.8 56.1 ± 4.3 
1
 Weights are represented as mg lipid/g liver ± SEM; n=7/genotype/diet 
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Table 13: Hepatic lipid accumulation in 4 day fed CMO-II KO mice compared to WT 
mice
1
. 
Diet WT CMO-II KO 
P-value 
Genotype Diet Interaction 
AIN-93 G 53.3 ± 3.4 62.2 ± 5.3 
0.001 0.38 0.68 
Tomato Powder 47.5 ± 1.5 67.7 ± 3.2 
Placebo Beadlet 48.8 ± 2.2 65.8 ± 3.4 
0.003 0.16 0.14 
Lycopene Beadlet 51.1 ± 2.8 73.4 ± 3.9 
1
 Weights are represented as mg lipid/g liver ± SEM; n=7/genotype/diet 
 
 
Table 14: Hepatic total cholesterol accumulation in 4 day fed CMO-II KO mice 
compared to WT mice
1
. 
Diet WT CMO-II KO 
P-value 
Genotype Diet Interaction 
AIN-93 G 81.0 ± 7.8 92.1 ± 5.5 
0.92 0.96 0.33 
Tomato Powder 92.6 ± 16.4 81.5 ± 4.0 
Placebo Beadlet 70.3 ± 4.9 95.5 ± 5.3 
0.003 0.15 0.32 
Lycopene Beadlet 74.0 ± 9.9 115.3 ± 6.1 
1
 Weights are represented as mg cholesterol/dL lipid solution ± SEM; n=7/genotype/diet 
 
 
Table 15: Serum total cholesterol accumulation in 30 day fed CMO-I KO mice compared 
to WT mice
1
. 
Diet WT CMO-I KO 
P-value 
Genotype Diet Interaction 
AIN-93 G 122 ± 5.4 101 ± 7.0 
0.002 0.32 0.95 
Tomato Powder 130 ± 4.2 106 ± 4.6 
Placebo Beadlet 126 ± 7.7 108 ± 15.4 
0.14 0.07 0.92 
Lycopene Beadlet 146 ± 9.4 128 ± 7.7 
1
 Weights are represented as mg cholesterol/dL serum ± SEM; n=7-8/genotype/diet 
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Table 16: Serum total cholesterol accumulation in 30 day fed CMO-II KO mice 
compared to WT mice
1
. 
Diet WT CMO-II KO 
P-value 
Genotype Diet Interaction 
AIN-93 G 122 ± 5.4 99.7 ± 3.3 
<0.001 0.93 0.25 
Tomato Powder 130 ± 4.2 92.2 ± 7.5 
Placebo Beadlet 126 ± 7.7 104 ± 6.0 
<0.001 0.62 0.03 
Lycopene Beadlet 146 ± 9.4 95.4 ± 7.9 
1
 Weights are represented as mg cholesterol/dL serum ± SEM; n=7-8/genotype/diet 
 
 
Table 17: Serum total cholesterol accumulation in 4 day fed CMO-I KO mice compared 
to WT mice
1
. 
Diet WT CMO-I KO 
P-value 
Genotype Diet Interaction 
AIN-93 G 119 ± 9.7 110 ± 5.5 
0.99 0.45 0.19 
Tomato Powder 115 ± 7.1 124 ± 4.3 
Placebo Beadlet 123 ± 8.9 120 ± 8.3 
0.01 0.29 0.03 
Lycopene Beadlet 133 ± 7.7 94.1 ± 5.6 
1
 Weights are represented as mg cholesterol/dL serum ± SEM; n=7-8/genotype/diet 
 
 
Table 18: Serum total cholesterol accumulation in 4 day fed CMO-II KO mice compared 
to WT mice
1
. 
Diet WT CMO-II KO 
P-value 
Genotype Diet Interaction 
AIN-93 G 119 ± 9.7 90.8 ± 6.0 
0.001 0.57 0.96 
Tomato Powder 115 ± 7.1 86.0 ± 6.7 
Placebo Beadlet 123 ± 8.9 93.4 ± 3.9 
<0.001 0.47 0.56 
Lycopene Beadlet 133 ± 7.7 94.4 ± 4.8 
1
 Weights are represented as mg cholesterol/dL serum ± SEM; n=7-8/genotype/diet 
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Chapter III 
Discussion and Future Directions 
Discussion 
 Consumption of fruits and vegetables is an essential part of a healthy diet and researchers 
have suggested that the carotenoids found in these food components have health benefits that go 
beyond vitamin A production (2). Although many of the health benefits of carotenoids have been 
implied, the metabolism of carotenoids within the organs is largely unknown and is an active 
area of research. Our lab has long term interest in the many actions of tomato carotenoids, 
especially lycopene. We are one of a few labs in the world to have CMO-I KO and CMO-II KO 
mouse colonies that can be used as models to investigate the metabolism of lycopene in vivo. In 
the past, our lab has been primarily focused on male CMO-I KO and CMO-II KO mice and had 
not extensively evaluated female CMO-I KO and CMO-II KO mice. Based primarily on work 
initially-published in CMO-I KO mice (47), we wanted to focus on lipid metabolism in our 
female KO mice.  
 We fed 29-31 week old female CMO-I KO, CMO-II KO and WT mice carotenoid-
containing diets (tomato powder or lycopene beadlet diet) or their respective controls (AIN-93G 
or placebo beadlet diets) for either 30 or 4 days. We analyzed the body and organ weights in the 
30 day study and found CMO-II KO mice to be smaller than WT mice in body weight and 
reproductive organ weights, as percent body weight, but higher weights in most non-reproductive 
organs compared to WT mice. CMO-I KO mice were not different in body weight compared to 
WT mice, but as was seen in CMO-II KO mice, their reproductive organ weights were 
significantly smaller.  
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 We were also interested in hepatic lipid accumulation in CMO-I KO and CMO-II KO 
mice. On average for both the 30 day and 4 day feeding study, CMO-I KO and CMO-II KO mice 
had significantly greater accumulation of hepatic lipids compared to WT mice. Contrary to what 
has been previously published on hepatic lipids for these genotypes (10, 47), we did not observe 
hepatic steatosis in our CMO-II KO mice and only saw minimal hepatic lipidosis in 25% of our 
CMO-I KO mice. Mice were fed a diet with low, but not clinically deficient, levels of vitamin A 
with normal fat levels, whereas in the other studies that reported hepatic steatosis in these strains, 
diets were either high in fat or deficient in vitamin A. We next wanted to investigate hepatic and 
serum cholesterol in our animals and found that CMO-II KO mice were significantly different 
from WT mice in hepatic and serum cholesterol levels in most diet groups. Finally, mRNA 
expression of PPARs and selected target genes were investigated. We found diet to have some 
impact on these genes. Tomato powder modulated the mRNA expression of PPARγ and its 
target gene, as well as PPARα. 
 Based on the results in this thesis we conclude that CMO-I KO and CMO-II KO mice 
have substantial phenotypic differences compared to WT mice in many measures of lipid status. 
However, feeding either a tomato powder or lycopene-supplemented diets to these animals had 
marginal effects compared to the effects seen with ablation of either carotenoid cleavage 
enzyme. It is clear that these enzymes, CMO-I and CMO-II, have functions that go beyond 
cleaving carotenoids and may play an important role in lipid metabolism.  
Future Directions  
In an assessment of the small amount of published literature, it is apparent that vitamin A 
levels in the rodent diet play an important part in the results seen in lipid metabolism in both the 
CMO-I KO mice and CMO-II KO mice (10, 24, 47). The hepatic vitamin A levels in our mice 
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were not measured and it would be interesting to know the differences between these genotypes 
regarding hepatic storage of vitamin A. Additionally, it would be of interest to measure the levels 
of lycopene metabolites in our tomato powder and lycopene-fed CMO-I KO and CMO-II KO 
mice to determine the in vivo metabolism of lycopene in these animals. It would also be 
interesting to compare the differences in lycopene metabolites between animals fed tomato 
powder or lycopene within the same genotype.   
Based on discrepancies in the literature regarding CMO-I KO and CMO-II KO mice and 
hepatic steatosis, there are at least two studies that would help clarify these results. In order to 
determine if hepatic steatosis could be prevented, or reversed, with introduction of carotenoids 
into the diet, two different studies would need to be performed. For one study, CMO-I KO, 
CMO-II KO and WT mice (n=720; 10 mice per genotype x 3 genotypes x 4 vitamin A level x 2 
fat levels x 3 treatments), at 20 weeks of age, would receive a high fat (30% w/w as used in 
Hessel et al.) or normal (10% w/w) fat diet with different levels of vitamin A (deficient 150, low 
1500, recommended 2400, high 14,000 IU/kg diet), with carotenoids (tomato or lycopene 
beadlets) or without (AIN-93G diet supplemented with placebo beadlets), and after 8 weeks of 
feeding the animals would be sacrificed (ages and length of feeding based on Hessel et al.). 
Hepatic lipid analysis and plasma lipids could be compared to determine if carotenoids, in 
conjunction with the different vitamin A status, could alter the fatty liver phenotype seen in these 
mice (10, 47).  
In the other study, animals (n=; 360, 10 per genotype x 3 genotypes x 4 vitamin A levels 
x 3 treatments) would be fed a high fat diet with low level of vitamin A (level may need to 
change if hepatic steatosis does not develop before placement onto experimental diets) after 
weaning, and after a predetermined number of weeks of feeding (determined by onset of hepatic 
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steatosis in these animals), mice would be placed on a control diet (each level of vitamin A, low 
fat AIN-93G supplemented with placebo beadlets) or a carotenoid-containing diet (each level of 
vitamin A, low fat; tomato powder supplemented with placebo beadlets or lycopene beadlet 
supplemented diet). These animals would be sacrificed after 8 weeks of feeding and liver lipids 
and plasma lipids would be compared to determine if lycopene or tomato powder could reverse 
hepatic steatosis.  
These studies would help to determine if the fatty liver phenotype of CMO-I KO mice 
and CMO-II KO mice in other studies was a result of vitamin A status or high fat feeding. By 
supplementing various levels of vitamin A to a high fat diet with or without carotenoids we 
would be able to determine which dietary factor(s) is predominantly contributing to this 
phenotype. We may also be able to determine at what level of vitamin A these carotenoids are 
able to prevent the onset of fatty liver. Additionally, by introducing lower fat diets to animals 
that already have hepatic steatosis, and further supplementing these diets with carotenoids, we 
could determine if low fat feeding alone or with the addition of carotenoids could reverse this 
phenotype. These results would help determine if dietary modifications can reverse hepatic 
steatosis.  
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